Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc. Common Stock (NY: BHC )

5.480 +0.310 (+6.00%)
Official Closing Price Updated: 4:10 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
The Profit and Protection Quantitative Stock-Picking System
Should you try growth investing or value investing? What about momentum strategies? Use this system as the ultimate guide to stock picking. 
Via InvestorPlace
Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022
Via ACCESSWIRE
Bausch Health Posts Q3 Profit Despite Lower Sales, Trims FY22 Outlook
Via Benzinga
Recap: Bausch Health Companies Q3 Earnings
Bausch Health Companies (NYSE:BHC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Bausch Health Announces Third-Quarter 2022 Results
Via ACCESSWIRE
Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference
Via ACCESSWIRE
Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge
Via ACCESSWIRE
Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference
Via ACCESSWIRE
Expert Ratings for Bausch Health Companies
Bausch Health Companies (NYSE:BHC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting
Via ACCESSWIRE
Bausch Health to Announce Third Quarter 2022 Results on Nov. 3
Via ACCESSWIRE
FedEx, UPS And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded lower this morning after recording losses in the previous session. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Why These 3 Stocks Are Off to Hot September Starts
Let’s look at what is behind the surprise rise in these three names—and whether they can continue to pace this month’s market rally. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Where Bausch Health Companies Stands With Analysts
Analysts have provided the following ratings for Bausch Health Companies (NYSE:BHC) within the last quarter: 
Via Benzinga
Why Is Bausch Health (BHC) Up 17% Today?
Today, investors in Bausch Health and BHC stock are cheering an announced $4 billion debt swap, which will push out the company's debt. 
Via InvestorPlace
Kroger, DocuSign And Other Big Gainers From Friday
U.S. stocks closed higher with the Nasdaq Composite surging 250 points on Friday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday
Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in... 
Via Benzinga
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Snap, Meta Platforms, Pinterest And Some Other Big Stocks Moving Higher On Wednesday
  Barnes & Noble Education, Inc. (NYSE: BNED) gained 16.8% to $2.64 after reporting upbeat quarterly sales. Bausch Health Companies Inc. (NYSE: BHC) gained 15.5% to $5.91. 
Via Benzinga
Why Nuwellis Surged Over 121%; Here Are 66 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Could This Company's HyBryte™ Provide A Safer, More Convenient Alternative To Cutaneous T-Cell Lymphoma Treatment?
Patients always have hope if their cancers are detected early. Thanks to advanced research and therapies, the earlier the cancer is diagnosed and treated, the better the chance of it being cured. 
Via Benzinga
Why Express Is Trading Higher By Over 21%, Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
Gainers Nuwellis, Inc. (NASDAQ: NUWE) shares jumped 140% to $1.5894 after the company announced new clinical data demonstrating 100% survival at 30 days following the use of ultrafiltration in... 
Via Benzinga
Bausch Health Companies Inc. (NYSE:BHC) Shareholder Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 08/12/2022 -- An investigation as announced over potential breaches of fiduciary duties by certain directors at Bausch Health Companies Inc. 
Via SBWire
7 Stock Price Predictions That Are Actually Worth Listening To
Investors may take advantage of analyst stock price predictions beyond the recent share price to discover promising investments. 
Via InvestorPlace
Recap: Bausch Health Companies Q2 Earnings
  Bausch Health Companies (NYSE:BHC) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Bausch Health Companies... 
Via Benzinga
This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday
Gainers Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal Holdings... 
Via Benzinga
BHC Stock Continues to Fall as Bausch Health Responds to Court Decision
Although Bausch Health promises to fight back against an unfavorable patent protection ruling, BHC stock is still hurting. 
Via InvestorPlace
Why Lottery.com Shares Are Trading Lower By 59%? 54 Stocks Moving In Friday's Mid-Day Session
Gainers Getty Images Holdings, Inc. (NYSE: GETY) shares jumped 106.7% to $21.69 after nearly 99.4% of shares were redeemed by CCNB shareholders. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
  
Via Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.